Cookie Einstellungen
Diese Webseite verwendet ausschließlich notwendige Cookies, die für die Funktion erforderlich sind. Marketing- und Statistik-Cookies kommen nicht zum Einsatz. Weitere Informationen finden Sie in unserer Datenschutzerklärung.
 Notwendig   Details einblenden
      OK      
Bitte logge Dich ein, um diese Funktion zu nutzen!
      OK      
x
Impact News +++ Sunbelt Rentals Appoints Ekta Singh-Bushell to Board of Directors (Business Wire) +++ TTEC Aktie +3,55%

News zum Sektor Gesundheit aus Naher Osten

Zum Sektor Gesundheit gehören Unternehmen der Pharmaka- & Biotechnologiebranche, Produzenten von medizintechnischen Geräten, Gesundheitsdienste, Kliniken und Pflegeeinrichtungen.
 >Gesundheit ETFs & Fonds 
Es sind 101 ETFs & Fonds zum Sektor Gesundheit bekannt.
 >Aktien zum Sektor Gesundheit 
Es sind 1559 Aktien zum Sektor Gesundheit bekannt.
 
13.07.26 - 19:45
Enlivex Ltd. (ENLV) Upgraded to Buy: Here′s Why (Zacks)
 
Enlivex Ltd. (ENLV) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy)....
13.07.26 - 14:03
Enlivex Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for Allocetra™ in Age-Related Knee Osteoarthritis (GlobeNewswire EN)
 
Nes-Ziona, Israel, July 13, 2026 (GLOBE NEWSWIRE) -- Enlivex Ltd. (Nasdaq: ENLV) ("Enlivex" or the "Company"), a quality longevity company, today announced that the U.S. Food and Drug Administration (FDA) has granted Regenerative Medicine Advanced Therapy (RMAT) designation to Allocetra™, the Company's clinical-stage immunotherapy, for the treatment of age-related symptomatic knee osteoarthritis (OA) in patients aged 64 and older....
13.07.26 - 13:18
Exklusiv: FDA erteilt Enlivex RMAT-Status für Kniearthrose-Therapie Allocetra (Investing.com DE)
 
Um den gesamten Artikel unter de.investing.com zu lesen, klicken Sie bitte auf die Überschrift...
13.07.26 - 13:15
Exclusive: FDA grants RMAT designation to Enlivex′s Allocetra for knee OA (Investing.com)
 
Um den gesamten Artikel unter investing.com zu lesen, klicken Sie bitte auf die Überschrift...
13.07.26 - 13:12
InMode expects Q2 revenue above estimates (SeekingAlpha)
 
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...
13.07.26 - 13:01
InMode to Report Second Quarter 2026 Financial Results on August 5, 2026, Expects Q2 Revenue Between $95.2M-$95.4M, Reiterates FY 2026 Revenue Guidance Between $365M-$375M (PR Newswire)
 
YOKNEAM, Israel, July 13, 2026 /PRNewswire/ -- InMode Ltd. (NASDAQ: INMD), a leading global provider of innovative medical technologies, announced today that it expects to release its financial results for the second quarter of 2026 before the Nasdaq market opens on Wednesday, August 5,......
10.07.26 - 13:03
InMode Confirms Receipt of Unsolicited Proposal (PR Newswire)
 
YOKNEAM, Israel, July 10, 2026 /PRNewswire/ -- InMode Ltd. (NASDAQ: INMD) (the "Company") confirmed that its Board of Directors (the "Board") has received the unsolicited letter and acquisition proposal from Steel Partners Holdings L.P. dated July 9, 2026. The Special Committee comprised......
09.07.26 - 16:06
Übernahmekampf um InMode: Steel Partners überbietet CEO-Offerte und treibt Aktie an (Investing.com DE)
 
Um den gesamten Artikel unter de.investing.com zu lesen, klicken Sie bitte auf die Überschrift...
09.07.26 - 15:45
Steel Partners offers to acquire InMode at $16.75 per share cash deal; stock rises premarket (SeekingAlpha)
 
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...
09.07.26 - 15:12
Futures Rise, Oil Drops As Markets Ignore Latest Middle East Airstrikes (ZeroHedge)
 
Futures Rise, Oil Drops As Markets Ignore Latest Middle East Airstrikes Futures are higher (although off session highs), and oil erased overnight gains as the market moved past the latest Middle-East flare up which saw the US military strike 90 Iranian targets for a second day and Tehran retaliated against American allies in the Persian Gulf. And like during previous escalations, this time nobody believes it will last. As of 8:00am ET S&P 500 futures rose 0.2% and Nasdaq 100 contracts gained 0.6% as semiconductor stocks advanced in Asia, Europe and US premarket trading after SK Hynix drew strong demand for its offering of ADRs. Mag7 stocks are mixed, with META tumbling on a Reuters report the company has signed long-term contracts for memory, networking gear and flash storage, refuting the market's expectation that the company is starting to ease back on capex spending. The FTSE 100 lags and is down 0.8% as AstraZeneca shares slump 9% after its Wainua drug failed to prevent heart problems. ....
09.07.26 - 14:48
InMode Aktie steigt nach Übernahmeangebot von Steel Partners über 16,75 Dollar (Investing.com DE)
 
Um den gesamten Artikel unter de.investing.com zu lesen, klicken Sie bitte auf die Überschrift...
09.07.26 - 14:36
Steel Partners Offers to Acquire InMode for $16.75 Per Share in Cash (Business Wire)
 
Superior Proposal Exceeds Conflicted CEO-Led $16.20 Insider Bid and Provides Optional Shareholder Rollover Demands the Board Take Immediate Action to Remove Incapable and Conflicted CEO Calls on Board to Form a Truly Independent Special Committee and Retain an Independent Investment Bank to Immediately Engage with Steel around Its Superior OfferNEW YORK--(BUSINESS WIRE)--Steel Partners Holdings L.P. (together with its affiliates, “Steel”), a significant, long-standing shareholder of InMode Ltd. (“InMode” or the “Company”) (NASDAQ: INMD), today issued a letter to the Board of Directors (the “Board”) of the Company, offering to acquire 100% of the shares of InMode for $16.75 per share in cash. The full text of the letter is below. July 9, 2026 VIA ELECTRONIC MAIL InMode Ltd. Tavor Building, Sha'ar Yokneam P.O. Box 533 Yokneam 2069206 Israel Attention: The Board of Directors Dear Members of the Board of Directors: Steel Partners Holdings L.P. (together with its affiliates, “Steel”) is a ...
07.07.26 - 19:45
Urogen Pharma (URGN) is a Great Momentum Stock: Should You Buy? (Zacks)
 
Does Urogen Pharma (URGN) have what it takes to be a top stock pick for momentum investors? Let's find out....
07.07.26 - 14:21
Enlivex announces 1-for-15 reverse stock split (SeekingAlpha)
 
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...
06.07.26 - 14:48
NeuroSense to Participate in Roth-Hosted KOL Webinar on the Future of ALS Treatment: "A Quest to Outrun ALS" (PR Newswire)
 
Featuring renowned ALS expert Prof. Jeremy Shefner, the discussion will address key unmet needs in ALS, trial endpoint design, and PrimeC's path forward CAMBRIDGE, Mass., July 6, 2026 /PRNewswire/ -- NeuroSense Therapeutics Ltd. (NASDAQ: NRSN) ("NeuroSense"), a late-stage clinical......
01.07.26 - 21:24
Steel Partners comes out against ‘value-destructive′ CEO-led buyout offer for InMode (SeekingAlpha)
 
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...
01.07.26 - 06:24
Is UroGen Pharma a Stock to Sell After Its Chief Medical Officer Let Go of 10,000 Shares? (Fool)
 
Focused on innovative cancer therapies, this biotech saw a notable insider sale amid a year of strong share price gains....
30.06.26 - 14:03
COLLPLANT BIOTECHNOLOGIES ANNOUNCES $2.6 MILLION PRIVATE PLACEMENT (PR Newswire)
 
REHOVOT, Israel, June 30, 2026 /PRNewswire/ -- CollPlant Biotechnologies (Nasdaq: CLGN), a regenerative and aesthetics medicine company developing innovative technologies and products based on its non-animal-derived, rhCollagen for tissue regeneration and medical aesthetics, today......
29.06.26 - 15:33
NeuroSense Achieves Primary Endpoint in Phase 2b ALS Study with Statistically Significant Reduction of TDP-43, the Defining Pathological Hallmark of ALS (PR Newswire)
 
First randomized, double-blind, placebo-controlled trial to demonstrate treatment-associated reduction of TDP-43 in people living with ALS TDP-43 pathology is present in more than 97% of ALS cases and is widely recognized as a central driver of disease progression PrimeC demonstrates......
26.06.26 - 14:27
DOMA PERPETUAL CAPITAL MANAGEMENT STRONGLY OPPOSES INMODE BUYOUT AS PROPOSED; PLANS TO VOTE AGAINST DEAL (PR Newswire)
 
DOMA ASSERTS THAT THE $16.20 PER SHARE OFFER MATERIALLY UNDERVALUES INMODE AND ITS LONG-TERM POTENTIAL DOMA BELIEVES THE BID EXPLOITS THE DEPRESSED VALUATIONS CREATED BY YEARS OF CEO-LED UNDERPERFORMANCE DOMA EXPLICITLY REJECTS THE CURRENT TERMS AND URGES THE BOARD TO UPLHOLD ITS......
>Behalte deine Investments mit realtime Kursen & News im Blick. Finde neue spannende Aktien! Registriere Dich und werde Mitglied!
Zitat des Tages: Ein Hafen ist ein reizvoller Aufenthalt für eine im Lebenskampf erschöpfte Seele. - Charles Baudelaire
>Aktienauflistung | >Aktienscreener | >Aktienkennzahlen | >Anleihen | >ETFs | >Fonds | >Branchen | >Länder | >Themen | >Redaktionen
Partner:    >TradegateBSX Börse | >Dukascopy | >TradingView | >Boersentreff- Partner

Börsentreff auf Facebook | Börsentreff auf X | Börsentreff auf Instagram

Copyright @ Boersentreff.de - Die Märkte im Blick!